Table 1

Schedule of assessments for the strategy to obtain warfarin or direct oral anticoagulant’s benefit by evaluating registry study

Study period
VisitV1V2V3V4
Timing (months, ±3)0*122436
Baseline assessmentFollow-upFollow-up complete/early termination
Informed consent
Screening/eligibility
Basic information†
Annual examinations‡
Laboratory tests§
Physiological tests¶, brain MRI, GDS
Other examinations**
Brain scintigraphy (SPECT)
Apolipoprotein E
Clinical outcomes/endpoints
  • ●: required, ○: optional.

  • *Information obtained within 3 months before informed consent can be used at enrolment.

  • †Basic information includes: (1) demographics and vital signs, (2) risk factors, (3) medical history, (4) medications, and (5) social factors and lifestyles.

  • ‡Annual examinations include vital signs and comprehensive geriatric assessment consisting of a fundamental activities of daily living (ADL) scale (Barthel Index), instrumental ADL scale (Lawton and Brody), the Mini-Mental State Examination, Montreal Cognitive Assessment and Clinical Dementia Rating scale.

  • §Laboratory tests include blood count, blood biochemistry, urinalysis and biomarkers such as high-sensitive C reactive protein, interleukin 6, N-terminal pro B-type natriuretic peptide, cardiac troponin T, and alpha-2-macroglobulin.

  • ¶Physiological tests include arterial stiffness assessment and echocardiography.

  • **Other examinations include carotid echography, neurophysiological, physical, and nutritional assessments.

  • GDS, Geriatric Depression Scale; SPECT, Single photon emission CT.